[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"olfactory-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:olfactory-dysfunction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,51,74,103,129,156,185,216,244,274,300,323],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100562228","slow-speed-uk-a-double-blind-randomised-feasibility-trial-100562228",false,"NCT06600438","Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial","Slow-SPEED-United Kingdom: A Double-Blind Randomised Feasibility Trial of a Remote Gamified Physical Activity Programme in Adults With Hyposmia.","Slow-SPEED","Inclusion criteria\n\n* Age ≥ 40 years\n* Objective hyposmia, defined as scoring below the 15th percentile (adjusted for age\u002Fsex) on UPSIT\n* Ability and willingness to provide written informed consent\n* Proficiency in written and spoken English sufficient to complete study procedures.\n* Willingness and ability to attend baseline (in-person), 9-month (remote), and 18-month (in-person) assessments.\n* Access to telephone or internet for interim communication. Specifically, in possession of a suitable smartphone (screen size minimum 4.6 inch; Android version 9 or iOS version 15 or newer).\n* Physical activity threshold: During the 4-week eligibility run-in, the mean daily step count must be \\\u003C7,000 steps\u002Fday, calculated over ≥21 valid days (a valid day = ≥10 hours wear time or ≥1,000 steps). If recruitment after the first 2 months is \\\u003C60-70% of target, and subject to TSC\u002FSponsor approval and REC amendment, eligibility may be broadened to \\\u003C10,000 steps\u002Fday (i.e. participants averaging 7,000-9,999 steps\u002Fday become eligible).\n\nExclusion criteria\n\n* Clinical diagnosis of PD, dementia, or other neurodegenerative conditions\n* Severe or unstable medical or psychiatric illness likely to impair participation\n* Use of agents known to alter olfaction (e.g. intranasal zinc, chronic corticosteroids)\n* Current enrolment in an interventional study within the past 3 months (standard research retention guidance).\n* Inability to complete study procedures in English, per investigator assessment\n* Unable to give consent\n* Participants not living independently in the community. Participants in nursing homes, hospitalised persons on in a non-institutionalised setting are excluded.\n* Subject's personal smartphone is Fitbit-incompatible i.e. Huawei P8 Lite; Huawei P9 Lite; Xiaomi Mi 6; Huawei P20 Lite\n* Activity level above threshold during eligibility run-in: mean daily step count ≥7,000 steps\u002Fday (or ≥10,000 steps\u002Fday if the broadened threshold is activated).","ALL","40 Years","100 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25],"NA","Slow-SPEED UK is an 18-month randomised, double-blind feasibility trial evaluating the delivery, adherence, and acceptability of a digitally supported physical activity programme in community-dwelling adults aged 40 and over with objectively confirmed hyposmia (reduced sense of smell) and low baseline physical activity.\n\nParticipants are randomly assigned 1:1 to either a full-dose activity-support programme (targeting a 100% increase in daily step count) or a very low-dose active control (targeting a 10% increase). Both arms are delivered via a smartphone application linked to a wearable activity monitor (Fitbit Charge 6), with personalised weekly goals expressed as relative percentages to maintain blinding. The study is not designed to test clinical efficacy.",[28,29,30],"Hyposmia","Olfactory Dysfunction","Anosmia",[28,32,33,34,35,36,37],"Physical activity","Feasibility randomized controlled trial","Wearable technology","Smartphone application","Olfactory dysfunction","Digital health intervention","RECRUITING","2026-06-24",{"date":41,"type":42},"2026-06-29","ACTUAL",{"date":44,"type":42},"2026-05-27",{"date":46,"type":22},"2027-10-31",{"name":48,"class":49},"Queen Mary University of London","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":50},"100641309","olfactory-dysfunction-in-aging-adults-100641309","NCT07660887","Olfactory Dysfunction in Aging Adults","Inclusion Criteria:\n\n* Age: 50 years or older\n* Ability to follow instructions and understand consent process in English\n* Adequate visual, auditory, or motor functioning to complete items in the test battery or availability of assistance or assist devices to complete tasks\n\nExclusion Criteria:\n\n\\- Vulnerable populations including prisoners or institutionalized individuals",true,"50 Years",{"count":60,"type":22},500,"OBSERVATIONAL","This prospective longitudinal cohort study will enroll adults aged 50 years and older to characterize olfactory dysfunction in aging. Participants will undergo comprehensive olfactory testing, cognitive assessment, biomarker collection, and imaging to identify clinically relevant phenotypes based on anatomic site of dysfunction. The study will also evaluate the impact of olfactory dysfunction on quality of life and identify baseline factors associated with changes in olfactory function over time.",[29],"NOT_YET_RECRUITING","2026-06-16",{"date":67,"type":42},"2026-06-22",{"date":69,"type":22},"2027-04-01",{"date":71,"type":22},"2032-04-30",{"name":73,"class":49},"Medical University of South Carolina",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100553134","dysfunction-of-olfaction-after-covid-19-infection-morphological-and-histomolecular-investigation-100553134","NCT06482138","Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation","Dysfunction of Olfaction After SARS-CoV-2 Infection: Morphological and Histomolecular Investigation of Olfactory Cleft Biopsies and Cytobrushes","DysOSMIC","Inclusion Criteria:\n\n* Olfactory Dysfunction group: Presence of evident OD (Parosmia, Threshold-Discrimination-Identification (TDI)-score ≤24, Subjective abnormal quantitative olfactory function; measured by a visual analogue score (VAS) of smell impairment ≥5\u002F10\n* Control group: No OD (TDI-score \\>30.5.)\n\nExclusion Criteria:\n\n* Presence of concomitant nasal mucosal pathology that might affect olfactory function or bias the study investigations\n* Use of anticoagulation therapy\n* Allergy to local anesthetics","18 Years","70 Years",{"count":85,"type":22},240,[25],"Investigation of the mechanisms of persistent SARS-CoV-2 associated olfactory dysfunction (OD) in patients with well-documented olfactory function. The investigators plan to collect olfactory cleft biopsies and cytobrushes in COVID-19 patients and controls.",[89,29],"Covid19",[29,91,92,30,28],"COVID-19","SARS-CoV-2","2026-04-30",{"date":95,"type":42},"2026-05-06",{"date":97,"type":42},"2024-01-24",{"date":99,"type":22},"2026-12-31",{"name":101,"class":49},"Universitaire Ziekenhuizen KU Leuven",7,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":50},"100634971","in-vivo-imaging-of-the-olfactory-epithelium-using-confocal-laser-endomicroscopy-100634971","NCT07546617","In Vivo Imaging of the Olfactory Epithelium Using Confocal Laser Endomicroscopy","In Vivo Imaging of Olfactory Epithelium in Humans With Olfactory Impairment Using Confocal Laser Endomicroscopy","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Undergoing endoscopic sinus or endonasal skull base surgery while under - general anesthesia where the nasal turbinate is accessible\n* Able to complete study questionnaires and psychophysical smell testing\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to fluorescein\n* Pregnancy\n* Medical instability precluding participation\n* Severe anatomic obstruction preventing safe access to the olfactory cleft and nasal turbinate\n* Any other safety concern identified by the investigator",{"count":111,"type":22},36,"This research is being done to better characterize the part of the nose that helps us smell. Currently, the only ways to study smell loss mostly rely on how people report it, rather than being able to see the underlying structures directly. In this study, we will use a special microscope (Confocal Laser Endomicroscopy (CLE)), originally developed for brain tissue, to look at the part of the nose that helps to detects smell. We hope to identify the tiny structures in that area and see how they might be different in people who have smell loss compared to those who do not.",[114,115,29],"Endonasal Surgery","Endoscopic Sinus Surgery",[117,115,118,119,29],"Confocal Laser Endomicroscopy","Smell Loss","Endonasal Skull Base Surgery","2026-04-16",{"date":122,"type":42},"2026-04-23",{"date":124,"type":22},"2026-07-01",{"date":126,"type":22},"2027-07-31",{"name":128,"class":49},"Dartmouth-Hitchcock Medical Center",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":137,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":50},"100572466","scents-of-progress-leveraging-a-novel-device-for-olfactory-training-in-older-adults-100572466","NCT06733636","Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults","SPLENDOR-OA; Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults","SPLENDOR-OA","Inclusion Criteria:\n\n* Adults 60 years of age or older.\n* English-speaking patients.\n* Patients with a diminished or lost sense of smell.\n* Patients who have not done smell training before\n\nExclusion Criteria:\n\n* Patients who are sensitive to any of the scents used in the study.\n* Patients with a diagnosis of congenital anosmia.","60 Years",{"count":139,"type":22},60,[25],"The goal of this clinical trial is to learn if ScentCare, a novel olfactory training device and accompanying companion web-based application, will lead to improved olfactory and well-being outcomes in elderly patients with Olfactory Dysfunction (OD). The main question it aims to answer is:\n\n\\- What effect does the olfactory training device (ScentCare) and accompanying companion web-based application have on olfaction?\n\nResearchers will compare ScentCare to solving Sudoku puzzles to see the effects of olfactory training using this novel device on olfaction. Previous studies have used Sudoku puzzles when studying the effect of smell training. Since smell training is thought to work by stimulating and engaging higher order cognition, Sudoku is a suitable activity for participants in the control group since it serves as a correlate with similar degree of stimulation.\n\nParticipants will:\n\n* Use ScentCare (intervention) or solve Sudoku puzzles (control) twice daily for 3 months.\n* Visit the clinic twice, once upon enrollment and once three months later.\n* Complete a formal smell test using Sniffin' Sticks smell test at the beginning of the study and again at the end of the study (3 months) during the initial and follow up visit.\n* Complete questionnaires at the beginning of the study and again at the end of the study (3 months) during the initial and follow up visit.",[29,118,30,28],[29,144,145,146,118,30,28],"Olfactory Training","Smell Training","Smell Training Device","2026-04-10",{"date":149,"type":42},"2026-04-13",{"date":151,"type":42},"2025-04-15",{"date":153,"type":22},"2027-03-31",{"name":155,"class":49},"Johns Hopkins University",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":50},"100629373","pandora-evaluation-of-platelet-rich-plasma-in-non-tumoural-odour-disorders-a-descriptive-pilot-study-100629373","NCT07473830","PANDORA: Evaluation of Platelet-rich Plasma in Non-tumoural Odour Disorders: a Descriptive Pilot Study.","PANDORA","Inclusion Criteria\n\n* Adults with persistent (\\>6 months) non-tumoural olfactory dysfunction: age-related degenerative olfactory dysfunction (DOD) or post-traumatic olfactory dysfunction (DOPT).\n* Objective olfactory impairment confirmed by Sniffin' Sticks Test (TDI ≤ 30.5\u002F48).\n* MRI within the last 6 months after onset excluding tumoural etiology or central cause.\n* Normal nasal endoscopy.\n* Affiliated to a social security system (or equivalent).\n* Written informed consent.\n\nExclusion Criteria\n\n* Inflammatory rhinosinus disease (e.g., nasal polyposis) or granulomatosis with polyangiitis.\n* Coagulation disorder.\n* Brain radiotherapy history or ongoing chemotherapy.\n* Olfactory disorder temporally linked to SARS-CoV-2 infection (delay \\\u003C1 month).\n* History of sinus or skull base surgery (except septoplasty\u002Fturbinoplasty\u002Frhinoseptoplasty).\n* Therapeutic-dose anticoagulants.\n* Refusal to discontinue chronic NSAID use if applicable.\n* Pregnancy\u002Flabor\u002Fbreastfeeding.\n* Vulnerable persons (deprived of liberty; legal protection; etc.).\n* Participation in another interventional study with ongoing exclusion period.","99 Years",{"count":165,"type":22},30,[25],"This is a prospective, single-center, single-arm, non-comparative descriptive pilot study evaluating autologous platelet-rich plasma (PRP) injections in adults with persistent (\\>6 months) non-tumoural olfactory dysfunction, either age-related degenerative olfactory dysfunction (DOD) or post-traumatic olfactory dysfunction (DOPT). Participants receive three PRP injections over 4 weeks (Day 0, Day 14, Day 28), with follow-up visits at Month 3 and Month 6 after the first injection. Olfactory function is assessed using the Sniffin' Sticks Test (TDI score). Patient-reported outcomes include SNOT-22 and a visual analog scale (VAS) for perceived olfactory impairment. Safety is assessed through adverse event collection.",[29,169,170],"Post-traumatic Olfactory Dysfunction","Age-related Degenerative Olfactory Dysfunction",[172,173,174,175,28,30],"Platelet-rich plasma","PRP","Sniffin' Sticks","Olfactory cleft","2026-03-17",{"date":178,"type":42},"2026-03-20",{"date":180,"type":22},"2026-05",{"date":182,"type":22},"2028-05",{"name":184,"class":49},"Hospices Civils de Lyon",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":57,"sex":17,"minAge":192,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":50},"100610077","phase-2-impact-of-smell-testing-on-health-outcomes-100610077","NCT07222891","Impact of Smell Testing on Health Outcomes","Validating the Impact of Smell Testing on Health Outcomes and Provider Engagement.","Inclusion Criteria:\n\n\\- Can read and understand English and have access to a reliable internet connection and a smart device or computer for the duration of the experimental sessions, unless they are part of community events in which smart devices are provided\n\nExclusion Criteria:\n\n\\- Known intolerance or allergy to any of the odor stimuli used","7 Years",{"count":194,"type":22},1000,[196],"PHASE2","Smell dysfunction is frequent yet neglected. The sense of smell plays a crucial role in signaling disease, safety, and overall quality of life. However, the significance of a functional sense of smell in terms of health and well-being is often overlooked until one experiences a loss of smell due to injury or disease. Research demonstrates that individuals are often not self-aware of their smell dysfunction (i.e. they do not spontaneously report smell dysfunction as a symptom), especially if the changes are gradual, as in normal aging. Patients with smell dysfunction experience a marked reduction in quality of life, poor mental health, nutritional health, and brain health as well as increased 5- and 10-year mortality in older adults. This study explores whether or not enabling healthcare providers to offer resources and guidance on coping strategies for smell dysfunction improves health and wellbeing in those who experience it.",[29,199],"Wellbeing",[201,202,203,204,205,206],"Olfactory testing","Smell dysfunction","Psychological health","Randomized clinical trial","Patient-centered care","Access to care","2025-10-29",{"date":209,"type":42},"2025-10-30",{"date":211,"type":22},"2025-11-01",{"date":213,"type":22},"2027-11-30",{"name":215,"class":49},"Monell Chemical Senses Center",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":50},"100604606","phase-3-topical-versus-injection-prp-for-olfactory-dysfunction-100604606","NCT07151703","Topical Versus Injection PRP for Olfactory Dysfunction","Carrier-Assisted Topical Application Versus Intranasal Injection of Autologous Platelet-Rich Plasma for Olfactory Dysfunction: A Randomized Controlled Trial","TOP-IN","Inclusion Criteria:\n\n* Aged between 18 and 80 years, regardless of sex\n* Subjective complaint of olfactory dysfunction with confirmed hyposmia or anosmia based on standardized olfactory testing\n* History of at least 3 months of prior olfactory training but with persistent olfactory complaints\n\nExclusion Criteria:\n\n* Congenital anosmia\n* Diagnosed neurological or structural brain abnormalities (e.g., brain tumor, major head trauma, stroke) with low likelihood of olfactory recovery\n* Inability or unwillingness to comply with study procedures or follow-up assessments","80 Years",{"count":139,"type":22},[227],"PHASE3","The goal of this clinical trial is to determine whether two different delivery methods of autologous platelet-rich plasma (PRP) can improve olfactory function in adults with persistent olfactory dysfunction lasting more than three months. The main questions it aims to answer are:\n\n1. Does carrier-assisted topical application of PRP lead to comparable or better improvement in smell function than intranasal injection of PRP?\n2. Which method provides greater patient comfort and fewer adverse effects?\n\nResearchers will compare carrier-assisted topical PRP application to intranasal PRP injection to see if one approach is more effective in restoring olfactory function.\n\nParticipants will:\n\n1. Receive a single PRP treatment delivered either by injection or via a PRP-soaked carrier placed into the olfactory cleft.\n2. Continue daily olfactory training for three months following the intervention.\n3. Undergo smell testing (Sniffin' Sticks) before and after treatment and complete quality-of-life questionnaires.",[29,30,28],[30,28,231,232,233],"Platelet-Rich Plasma (PRP)","Intranasal Injection","Randomized Controlled Trial","2025-08-25",{"date":236,"type":42},"2025-09-03",{"date":238,"type":22},"2025-10-01",{"date":240,"type":22},"2028-12-31",{"name":242,"class":243},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":251,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":253,"conditions":254,"keywords":260,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":273},"100583292","the-impact-of-endoscopic-endonasal-skull-base-surgery-on-olfaction-100583292","NCT06874426","The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction","Endo-Olfact","Inclusion Criteria:\n\n* Adult patients scheduled for endoscopic endonasal skull base surgery\n\nExclusion Criteria:\n\n* Pre-existing anosmia\n* Patients has a history of previous endoscopic endonasal skull base surgery",{"count":252,"type":22},154,"In this study, the research team will investigate the incidence and etiology of olfactory dysfunction following endoscopic endonasal skull base surgery, by combining clinical assessments with histomolecular analysis.",[255,256,257,258,259,29],"Meningioma","Pituitary Disease","Pituitary Adenoma","Craniopharyngioma","Endoscopic Pituitary Surgery",[261,262,263,264],"olfactory dysfunction","trigeminal dysfunction","endoscopic endonasal skull base surgery","pituitary surgery","2025-04-17",{"date":267,"type":42},"2025-04-23",{"date":269,"type":42},"2025-03-18",{"date":271,"type":22},"2029-09",{"name":101,"class":49},3,{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":224,"enrollmentInfo":281,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":284,"conditions":285,"keywords":287,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":50},"100580419","the-effect-of-modified-olfactory-training-on-postoperative-olfactory-dysfunction-in-patients-with-crs-100580419","NCT06837051","The Effect of Modified Olfactory Training on Postoperative Olfactory Dysfunction in Patients With CRS","Protocol for a Randomized Controlled Trial Evaluating the Effect of Modified Olfactory Training on Postoperative Olfactory Dysfunction in Patients With Chronic Rhinosinusitis","Inclusion Criteria:\n\n1. A diagnosis of CRSsNP based on the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 (EPOS20).\n2. The duration after endoscopic sinus surgery is 3months.\n3. Olfactory dysfunction confirmed with the Sniffin's Sticks psychophysical test (TDI score≦30.5) .\n4. Willingness to participate in this study and sign the informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Patients with olfactory impairment due to traumatic, congenital, toxic\u002Fdrug-induced causes, tumors, or post-upper respiratory infections.\n2. Lund-Mackay olfactory cleft score \\> 0.\n3. Patients with severe comorbidities, such as malignant tumors.\n4. Current or planned pregnancy prior to the end of study.\n5. Patients who are unable to complete the study or are unable to comply with the requirements of the study (such as inability to tolerate olfactory function testing and treatment, memory or behavioral abnormalities, depression, smoking, heavy alcohol use, previous delinquent behavior)",{"count":282,"type":22},213,[25],"The goal of this clinical trial is to validate the effectiveness of the modified olfactory training device, the main questions it aims to answer are:\n\nIs it possible that the device can treat postoperative olfactory dysfunction in patients with chronic sinusitis? Compared to the conventional device, how efficient is the modified olfactory training device for treating postoperative olfactory dysfunction in patients with chronic sinusitis?",[29,286],"Chronic Rhinosinusitis",[261,288,289,290],"chronic rhinosinusitis","endoscopic sinus surgery","olfactory training","2025-02-14",{"date":293,"type":42},"2025-02-20",{"date":295,"type":22},"2025-03-14",{"date":297,"type":22},"2027-03-14",{"name":299,"class":49},"Peking University Third Hospital",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":224,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":309,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":50},"100579854","the-efficacy-of-modified-olfactory-training-method-for-patients-with-post-viral-olfactory-dysfunction-100579854","NCT06829706","The Efficacy of Modified Olfactory Training Method for Patients With Post-viral Olfactory Dysfunction","A Randomized Trail Protocol to Access Efficacy of Modified Olfactory Training Method for Patients With Post-viral Olfactory Dysfunction","Inclusion Criteria:\n\n1. Age 18-80 years old, gender not limited.\n2. Patients diagnosed with olfactory dysfunction following infections of the upper respiratory tract, as determined by Sniffin' Sticks test (including TDI value test).\n3. Voluntarily signs the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with post-traumatic olfactory dysfunction, rhinosinusitis-related dysfunction and olfactory dysfunction caused by other reasons.\n2. Patients with concomitant sinonasal disease.\n3. Patients with chronic diseases, such as hypertension, diabetes, bronchopneumonia, chronic obstructive pulmonary disease, etc.\n4. Patients with serious coexisting diseases: such as malignant tumors, etc., with a life expectancy of less than 2 years.\n5. Patients who cannot tolerate olfactory function testing and treatment.\n6. Patients who have taken oral glucocorticoids, antibacterial drugs, anti-leukotrienes, antihistamines, or received olfactory training within four weeks will be excluded.\n7. Patients who are receiving treatment that affects olfactory recovery.\n8. Patients with smoking habits.\n9. Patients who are already or plan to be pregnant.\n10. According to the judgment of the researchers, the patient cannot complete this study or cannot comply with the requirements of this study (such as memory or behavior abnormalities, depression, heavy drinking, previous breach of contract).\n11. Patients who did not consent for participating in the study.",{"count":308,"type":22},150,[25],"The goal of this clinical trial is to validate the effectiveness of the modified olfactory training device, the main questions it aims to answer are: Is the modified olfactory training device effective in treating patients with post-viral olfactory dysfunction? Compared to the conventional device, how efficient is the modified olfactory training device for improving olfactory function?",[29,312],"Post Viral Olfactory Dysfunction (PVOD)",[144,314,312],"Modified Olfactory Training Device","2025-02-13",{"date":317,"type":42},"2025-02-17",{"date":319,"type":22},"2025-03-22",{"date":321,"type":22},"2027-05-22",{"name":299,"class":49},{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":17,"minAge":137,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":334,"conditions":335,"keywords":339,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":345,"leadSponsor":346,"locationsCount":50},"100579248","the-efficacy-of-modified-olfactory-training-for-mci-high-risk-individuals-100579248","NCT06821828","The Efficacy of Modified Olfactory Training for MCI High-Risk Individuals","Assessing Modified Olfactory Training to Prevent Cognitive Decline in MCI High-Risk Individuals: A Randomized Controlled Trial Protocol","Inclusion Criteria:\n\n1. Age and Gender: Individuals aged 60-80 years, regardless of gender.\n2. Diagnosis of Idiopathic Olfactory Dysfunction: overall TDI score below 30.75 points using the Sniffin' Sticks test. Without olfactory impairment due to traumatic, sinusitis-related, congenital, toxic\u002Fdrug-induced causes, post-operative conditions, tumors, or post-upper respiratory infections.\n3. Diagnosis of Subjective Cognitive Decline: Montreal Cognitive Assessment (MoCA) score \\>24 for middle school level and above, \\>19 for elementary school level, and \\>13 for illiterate individuals. Amyloid β (Aβ) deposition in the brain (defined as Aβ42 \\\u003C 550 ∼ 813 pg\u002Fml)， the higher Formula of Hulstaert (defined as \\[(Aβ42\u002F(240 + 1.18 × tau) ≤1\\]）, and hippocampus atrophy.\n4. Consent: Willingness to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Comorbid Chronic Diseases or Severe Concurrent Illnesses: Individuals with conditions such as hypertension, diabetes, bronchopneumonia, malignant tumors， or chronic obstructive pulmonary disease.\n\n4\\. Recent Medication Use: Exclusion of participants who have taken corticosteroids, antimicrobials, leukotriene antagonists, or antihistamines within the last four weeks.\n\n5\\. Inability to Comply with Study Requirements: Based on the researcher's judgment, individuals who are unable to tolerate olfactory function tests and treatment， complete the study or comply with its requirements due to memory or behavioral abnormalities, depression, severe alcohol consumption, or previous non-compliance.","90 Years",{"count":332,"type":22},114,[25],"The goal of this clinical trial is to validate the effectiveness of the modified olfactory training device, the main questions it aims to answer are: Is it possible that the device can delay the progression of MCI in older adults? Compared to the conventional device, how efficient is the modified olfactory training device for improving cognitive function?",[336,29,337,338],"Subjective Cognitive Decline (SCD)","Mild Cognitive Impairment (MCI)","ELDERLY PEOPLE",[337,336,290,340,29],"elderly population","2025-02-06",{"date":343,"type":42},"2025-02-12",{"date":319,"type":22},{"date":321,"type":22},{"name":299,"class":49}]